Aimmune has its answer on peanut drug's status, but how FDA proceeds still unclear

Aimmune has its answer on peanut drug's status, but how FDA proceeds still unclear

Source: 
BioSpace
snippet: 

Aimmune Therapeutics expects to know by the end of March whether the Food and Drug Administration will proceed with review of its peanut allergy treatment, the company said Thursday, clearing up some lingering confusion regarding the drug's regulatory status.